These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 7631893)

  • 21. V1- and V2-receptor contributions to ovine fetal renal and cardiovascular responses to vasopressin.
    Ervin MG; Ross MG; Leake RD; Fisher DA
    Am J Physiol; 1992 Apr; 262(4 Pt 2):R636-43. PubMed ID: 1566929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
    Naitoh M; Suzuki H; Murakami M; Matsumoto A; Ichihara A; Nakamoto H; Yamamura Y; Saruta T
    Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
    Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
    J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity of the renal medullary circulation to plasma vasopressin.
    Franchini KG; Cowley AW
    Am J Physiol; 1996 Sep; 271(3 Pt 2):R647-53. PubMed ID: 8853387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation.
    Aki Y; Tamaki T; Kiyomoto H; He H; Yoshida H; Iwao H; Abe Y
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):331-6. PubMed ID: 7511766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of vasopressin V2 receptors in modulation of the renal cortico-papillary NaCl gradient.
    Kompanowska-Jezierska E; Dobrowolski L; Sadowski J
    Pflugers Arch; 1994 Oct; 428(3-4):410-4. PubMed ID: 7816563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of activation of vasopressin-V1-receptors on regional kidney blood flow and glomerular arteriole diameters.
    Correia AG; Denton KM; Evans RG
    J Hypertens; 2001 Mar; 19(3 Pt 2):649-57. PubMed ID: 11327642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [3H]AVP binding to rat renal tubular receptors during long-term treatment with an antagonist of arginine vasopressin.
    Mah SC; Whitebread SE; De Gasparo M; Hofbauer KG
    Peptides; 1988; 9(3):595-600. PubMed ID: 3420014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of renal medullary infusion of a vasopressin V1 agonist on renal antihypertensive mechanisms in rabbits.
    Bergström G; Evans RG
    Am J Physiol; 1998 Jul; 275(1):R76-85. PubMed ID: 9688963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of rat renal medullary Na+/K(+)-ATPase by arginine vasopressin is mediated by the V2 receptor.
    Charlton JA; Baylis PH
    J Endocrinol; 1990 Nov; 127(2):213-6. PubMed ID: 2174453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vasopressin-stimulated phosphoinositide hydrolysis in cultured rat inner medullary collecting duct cells is mediated by the oxytocin receptor.
    Teitelbaum I
    J Clin Invest; 1991 Jun; 87(6):2122-6. PubMed ID: 1645753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diversity of responses of renal cortical and medullary blood flow to vasoconstrictors in conscious rabbits.
    Evans RG; Madden AC; Denton KM
    Acta Physiol Scand; 2000 Aug; 169(4):297-308. PubMed ID: 10951121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate.
    Luk J; Ajaelo I; Wong V; Wong J; Chang D; Chou L; Reid IA
    Am J Physiol; 1993 Sep; 265(3 Pt 2):R524-9. PubMed ID: 8214142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasopressin-induced calcium signaling in cultured hippocampal neurons.
    Brinton RD; Gonzalez TM; Cheung WS
    Brain Res; 1994 Oct; 661(1-2):274-82. PubMed ID: 7834378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vasopressin-induced calcium signaling in cultured hippocampal neurons.
    Brinton RD; Gonzalez TM; Cheung WS
    Brain Res; 1994 Dec; 667(1):151-9. PubMed ID: 7895079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Through V2, not V1 receptor relating to endogenous opiate peptides, arginine vasopressin in periaqueductal gray regulates antinociception in the rat.
    Yang J; Chen JM; Liu WY; Song CY; Lin BC
    Regul Pept; 2006 Dec; 137(3):156-61. PubMed ID: 17011056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Johnston CI
    Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central cardiovascular effects of AVP and AVP analogs with V1, V2 and 'V3' agonistic or antagonistic properties in conscious dog.
    Noszczyk B; Lon S; Szczepańska-Sadowska E
    Brain Res; 1993 Apr; 610(1):115-26. PubMed ID: 8518919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of phosphoinositide hydrolysis in renal medulla by vasopressin.
    Garg LC; Kapturczak E
    Endocrinology; 1990 Sep; 127(3):1022-7. PubMed ID: 2167202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs.
    Liard JF
    Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.